|
1
|
London WB, Castleberry RP, Matthay KK, et
al: Evidence for an age cutoff greater than 365 days for
neuroblastoma risk group stratification in the Children’s Oncology
Group. J Clin Oncol. 23:6459–6465. 2005.PubMed/NCBI
|
|
2
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chu CM, Rasalkar DD, Hu YJ, Cheng FW, Li
CK and Chu WC: Clinical presentations and imaging findings of
neuroblastoma beyond abdominal mass and a review of imaging
algorithm. Br J Radiol. 84:81–91. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pavlidis N, Stahel R, Clarke M and
Djulbegovic B: Cancer treatment reviews welcomes submission of the
Cochrane Reviews. Cancer Treat Rev. 32:243–244. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Verissimo CS, Molenaar JJ, Fitzsimons CP
and Vreugdenhil E: Neuroblastoma therapy: what is in the pipeline?
Endocr Relat Cancer. 18:R213–R231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hara J: Development of treatment
strategies for advanced neuroblastoma. Int J Clin Oncol.
17:196–203. 2012. View Article : Google Scholar
|
|
7
|
Arévalo JC and Wu SH: Neurotrophin
signaling: many exciting surprises! Cell Mol Life Sci.
63:1523–1537. 2006.PubMed/NCBI
|
|
8
|
Huang EJ and Reichardt LF: Trk receptors:
roles in neuronal signal transduction. Annu Rev Biochem.
72:609–642. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Soppet D, Escandon E, Maragos J, et al:
The neurotrophic factors brain-derived neurotrophic factor and
neurotrophin-3 are ligands for the trkB tyrosine kinase receptor.
Cell. 65:895–903. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Odate S, Nakamura K, Onishi H, et al:
TrkB/BDNF signaling pathway is a potential therapeutic target for
pulmonary large cell neuroendocrine carcinoma. Lung Cancer.
79:205–214. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dionne CA, Camoratto AM, Jani JP, et al:
Cell cycle-independent death of prostate adenocarcinoma is induced
by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer
Res. 4:1887–1898. 1998.PubMed/NCBI
|
|
12
|
Miknyoczki SJ, Lang D, Huang L,
Klein-Szanto AJ, Dionne CA and Ruggeri BA: Neurotrophins and Trk
receptors in human pancreatic ductal adenocarcinoma: expression
patterns and effects on in vitro invasive behavior. Int J Cancer.
81:417–427. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang YT, Lai PC, Wu CC, et al: BDNF
mediated TrkB activation is a survival signal for transitional cell
carcinoma cells. Int J Oncol. 36:1469–1476. 2010.PubMed/NCBI
|
|
14
|
Sclabas GM, Fujioka S, Schmidt C, et al:
Overexpression of tropomysin-related kinase B in metastatic human
pancreatic cancer cells. Clin Cancer Res. 11:440–449.
2005.PubMed/NCBI
|
|
15
|
Patani N, Jiang WG and Mokbel K:
Brain-derived neurotrophic factor expression predicts adverse
pathological and clinical outcomes in human breast cancer. Cancer
Cell Int. 11:232011. View Article : Google Scholar
|
|
16
|
Chen PS, Su JL and Hung MC: Dysregulation
of microRNAs in cancer. J Biomed Sci. 19:902012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou H, Guo JM, Lou YR, et al: Detection
of circulating tumor cells in peripheral blood from patients with
gastric cancer using microRNA as a marker. J Mol Med. 88:709–717.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Teshima K, Nara M, Watanabe A, et al:
Dysregulation of BMI1 and microRNA-16 collaborate to enhance an
anti-apoptotic potential in the side population of refractory
mantle cell lymphoma. Oncogene. May 20–2013.(Epub ahead of print).
View Article : Google Scholar
|
|
19
|
Cece R, Barajon I and Tredici G: Cisplatin
induces apoptosis in SH-SY5Y human neuroblastoma cell line.
Anticancer Res. 15:777–782. 1995.PubMed/NCBI
|
|
20
|
Zhang YX, Yue Z, Wang PY, et al: Cisplatin
upregulates MSH2 expression by reducing miR-21 to inhibit A549 cell
growth. Biomed Pharmacother. 67:97–102. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Middlemas DS, Kihl BK, Zhou J and Zhu X:
Brain-derived neurotrophic factor promotes survival and
chemoprotection of human neuroblastoma cells. J Biol Chem.
274:16451–16460. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Numakawa T, Suzuki S, Kumamaru E, Adachi
N, Richards M and Kunugi H: BDNF function and intracellular
signaling in neurons. Histol Histopathol. 25:237–258.
2010.PubMed/NCBI
|
|
23
|
Xiong L, Deng X, Wen Y, Yang Z and Miao X:
Association of BDNF and BMPR1A with clinicopathologic parameters in
benign and malignant gallbladder lesions. World J Surg Oncol.
11:802013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar
|
|
25
|
Guo WG, Zhang Y, Ge D, et al:
Bioinformatics analyses combined microarray identify the
desregulated microRNAs in lung cancer. Eur Rev Med Pharmacol Sci.
17:1509–1516. 2013.PubMed/NCBI
|
|
26
|
Kefas B, Godlewski J, Comeau L, et al:
microRNA-7 inhibits the epidermal growth factor receptor and the
Akt pathway and is down-regulated in glioblastoma. Cancer Res.
68:3566–3572. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiong S, Zheng Y, Jiang P, Liu R, Liu X
and Chu Y: MicroRNA-7 inhibits the growth of human non-small cell
lung cancer A549 cells through targeting BCL-2. Int J Biol Sci.
7:805–814. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bhattacharya R, Nicoloso M, Arvizo R, et
al: MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer.
Cancer Res. 69:9090–9095. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bonci D, Coppola V, Musumeci M, et al: The
miR-15a-miR-16-1 cluster controls prostate cancer by targeting
multiple oncogenic activities. Nat Med. 14:1271–1277. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ma Q, Wang X, Li Z, et al: microRNA-16
represses colorectal cancer cell growth in vitro by
regulating the p53/survivin signaling pathway. Oncol Rep.
29:1652–1658. 2013.PubMed/NCBI
|
|
31
|
Lee ST, Chu K, Jung KH, et al: miR-206
regulates brain-derived neurotrophic factor in Alzheimer disease
model. Ann Neurol. 72:269–277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mellios N, Huang HS, Grigorenko A, Rogaev
E and Akbarian S: A set of differentially expressed miRNAs,
including miR-30a-5p, act as post-transcriptional inhibitors of
BDNF in prefrontal cortex. Hum Mol Genet. 17:3030–3042. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mellios N, Huang HS, Baker SP, Galdzicka
M, Ginns E and Akbarian S: Molecular determinants of dysregulated
GABAergic gene expression in the prefrontal cortex of subjects with
schizophrenia. Biol Psychiatry. 65:1006–1014. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Imam JS, Plyler JR, Bansal H, et al:
Genomic loss of tumor suppressor miRNA-204 promotes cancer cell
migration and invasion by activating AKT/mTOR/Rac1 signaling and
actin reorganization. PLoS One. 7:e523972012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xiang Q, Tang H, Yu J, Yin J, Yang X and
Lei X: MicroRNA-98 sensitizes cisplatin-resistant human lung
adenocarcinoma cells by up-regulation of HMGA2. Pharmazie.
68:274–281. 2013.PubMed/NCBI
|
|
36
|
Chauffert B, Dimanche-Boitrel MT, Garrido
C, et al: New insights into the kinetic resistance to anticancer
agents. Cytotechnology. 27:225–235. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu L, Lian J, Zhang H, et al:
MicroRNA-302a sensitizes testicular embryonal carcinoma cells to
cisplatin-induced cell death. J Cell Physiol. April 27–2013.(Epub
ahead of print). View Article : Google Scholar
|
|
38
|
Ryan J, Tivnan A, Fay J, et al:
MicroRNA-204 increases sensitivity of neuroblastoma cells to
cisplatin and is associated with a favourable clinical outcome. Br
J Cancer. 107:967–976. 2012. View Article : Google Scholar : PubMed/NCBI
|
